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The neuromodulator melatonin synchronizes circadian rhythms and related 
physiological functions through the actions of two G-protein-coupled receptors: MT1 
and MT2. Circadian release of melatonin at night from the pineal gland activates 
melatonin receptors in the suprachiasmatic nucleus of the hypothalamus, 
synchronizing the physiology and behaviour of animals to the light–dark cycle1–4. The 
two receptors are established drug targets for aligning circadian phase to this cycle in 
disorders of sleep5,6 and depression1–4,7–9. Despite their importance, few in vivo active 
MT1-selective ligands have been reported
2,8,10–12, hampering both the understanding of 
circadian biology and the development of targeted therapeutics. Here we docked 
more than 150 million virtual molecules to an MT1 crystal structure, prioritizing 
structural fit and chemical novelty. Of these compounds, 38 high-ranking molecules 
were synthesized and tested, revealing ligands with potencies ranging from 
470 picomolar to 6 micromolar. Structure-based optimization led to two selective 
MT1 inverse agonists—which were topologically unrelated to previously explored 
chemotypes—that acted as inverse agonists in a mouse model of circadian re-
entrainment. Notably, we found that these MT1-selective inverse agonists advanced 
the phase of the mouse circadian clock by 1.3–1.5 h when given at subjective dusk, an 
agonist-like effect that was eliminated in MT1- but not in MT2-knockout mice. This 
study illustrates the opportunities for modulating melatonin receptor biology 
through MT1-selective ligands and for the discovery of previously undescribed, in vivo 
active chemotypes from structure-based screens of diverse, ultralarge libraries.
The recent determination of the crystal structures of the MT1 and MT2 
receptors13,14 afforded us the opportunity to seek previously unde-
scribed chemotypes with new functions, including MT1-selective 
ligands, by computational docking of an ultralarge make-on-demand 
library15, seeking molecules that complemented the main ligand-bind-
ing (orthosteric) site of the receptor. Given the similarity of the MT1 and 
MT2 sites—in which 20 out of 21 residues are identical—and the chal-
lenges of docking for selectivity16, we sought to prioritize previously 
undescribed, high-ranking chemotypes from the docking screen that 
were unrelated to known melatonin receptor ligands and expected 
that these molecules interacted differentially with the two melatonin 
receptor types17–19.
We docked more than 150 million ‘lead-like’ molecules, characterized 
by favourable physical properties from ZINC (http://zinc15.docking.
org)15,20. These largely make-on-demand molecules have not previously 
been synthesized, but are usually accessible by two-component reac-
tions. Use of complex building blocks in these reactions biases towards 
diverse, structurally interesting molecules15,20. Each library molecule 
was sampled in an average of more than 1.6 million poses (orientations 
× conformations) in the MT1 orthosteric site
13 by DOCK3.721, generat-
ing more than 72 trillion complexes for the library overall and scoring 
each pose for physical complementarity to the receptor site21. Seek-
ing diversity, the top 300,000 scoring molecules were clustered by 
topological similarity, resulting in 65,323 clusters, and those that were 
similar to known MT1 and MT2 ligands from ChEMBL23
22 were eliminated 
(Methods, Fig. 1 and Extended Data Table 1).
The best-scoring molecules from each of the top 10,000 clusters 
were inspected for engagement with residues that recognize ligands 
in the MT1 crystal structure
13,14 and for new polar partners in the MT1 
site. In the docked complexes, these included hydrogen bonds with 
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Discovery of chemotypes with distinct efficacies
These active molecules included both agonists and inverse agonists, 
consistent with the emphasis on chemotype novelty (Fig. 1 and Extended 
Data Table 1). This novelty is supported quantitatively by their low topo-
logical similarity to known melatonin receptor ligands24, and visually 
by comparison of the new ligands to their closest analogues among the 
known compounds (Extended Data Table 1). The different chemotypes 
often engaged the same residues that recognize 2-phenylmelatonin in 
the crystal structures. Examples include the hydrogen-bond interac-
tions with N1624.60 made by the methoxy group of 2-phenylmelatonin 
that, in the docked models, were made by esters (ZINC92585174), 





































































































































































Fig. 1 | Large library docking finds novel, potent melatonin receptor ligands. 
a, Docking for new melatonin receptor chemotypes from the make-on-demand 
library. b, Docked pose of ZINC159050207, an hMT1/hMT2 non-selective 
agonist with low nanomolar activity. c, Docked pose of ZINC157665999, an 
MT2-selective inverse agonist. In b and c, the crystallographic geometry of 
Q181ECL2, N1624.60, T178ECL2 and N2556.52, and hydrogen bonds with the 
backbone atoms of A1584.56, G1043.29 and F179ECL2. Conformationally 
strained molecules and those with unsatisfied hydrogen-bond donors 
were deprioritized23. Within the best-scoring clusters, all members were 
inspected and the one that best fitted these criteria was prioritized. 
Ultimately, 40 molecules with ranks ranging from 16 to 246,721, or 
the top 0.00001% to top 0.1% of the more than 150 million docked 
molecules, were selected for de novo synthesis and testing. Of the 38 
molecules that were successfully synthesized (a 95% fulfilment rate), 
15 had activity at either or both of the human MT1 and MT2 receptors 
in functional assays (Fig. 1 and Extended Data Table 1), a hit rate of 39% 
(calculated as the number of active compounds/number of physically 
tested compounds).
2-phenylmelatonin is shown in transparent blue, for context. d, The initial 15 
docking actives are shown, highlighting groups that correspond to melatonin’s
acetamide side chain (blue) and its 5-methoxy-indole (red) in their docked 
poses and receptor interactions. Boxed molecules are inverse agonists.
Similarly, whereas 2-phenylmelatonin stacks an indole with F179ECL2, 
the docked ligands stack benzoxazines (ZINC482850041), thiophenes 
(ZINC419113878) and furans (ZINC433313647). Whereas 2-phenylme-
latonin forms hydrogen bonds with Q181ECL2 through its acetamide, the 
docked ligands use esters or pyridines (Fig. 1). The new ligands also 
dock to interact with new residues, including hydrogen bonds with 
T178ECL2, N2556.52, A1584.56, G1043.29 and F179ECL2 (Fig. 1b, c and Extended 
Data Fig. 3a–d).
Consistent with docking against an agonist-bound MT1 structure, 
four of the ligands were MT1-selective agonists (Extended Data Fig. 1a, 
b), with half-maximum effective concentration (EC50) values in the 
2–6 μM range, and without detectable MT2 activity at concentrations 
of up to 30 μM: ZINC419113878, ZINC151209032, ZINC353044322 
and ZINC182731037. Notably, ZINC159050207—although it was not 
selective between the receptor types—is a 1 nM MT1 agonist and is one 
of the most-potent molecules found directly from a docking screen25–30 
(Fig. 1b, Extended Data Table 1 and Extended Data Fig. 1c, d). Admit-
tedly, many ligands were just as active at the MT2 receptor or were 
even selective for it (Extended Data Table 1 and Extended Data Fig. 1). 
Thus, although the initial docking against the MT1 structure found 
new, potent chemotypes, and some of these were type-selective, they 
were just as likely to prefer the MT2 type as the MT1 type. This attests to 
both the strengths and weaknesses of chemotype novelty as a strategy 
for compound prioritization, and the need for further optimization.
We sought to improve 12 of these chemotype families, selecting ana-
logues from the make-on-demand library. Several thousand such mol-
ecules were docked into the MT1 site (see Methods and Extended Data 
Table 2). Of the 131 synthesized and tested, 94 analogues had activity at 
either or both the MT1 or MT2 melatonin receptors at concentrations 
of ≤10 μM (Extended Data Table 2, Extended Data Fig. 2 and Supple-
mentary Table 1); of the 12 chemotype families, 5 showed improved 
potency. While this structure-based analogue-finding method could 
often find more-potent ligands, the efficacy, selectivity and bias of 
these compounds were sensitive to small structural changes (Extended 
Data Fig. 3).
We were particularly interested in type-selective ligands with in vivo 
efficacy, as these are unreported in the field. We investigated two MT1-
selective inverse agonists, ZINC555417447 and ZINC157673384, and 
a selective MT2 agonist, ZINC128734226 (from here on referred to as 
UCSF7447, UCSF3384 and UCSF4226, respectively), for their affinities 
(Fig. 2 and Supplementary Data 3, 4), in vitro signalling, pharmacokinet-
ics (Extended Data Table 3), selectivity to mouse as well as the human 
melatonin receptors (Fig. 2 and Supplementary Data 3, 4), and for their 
efficacies in mouse models of circadian behaviour (Fig. 3 and Extended 
Data Figs. 4, 5, 7). As expected, UCSF7447 and UCSF3384 competed for 
2-[125I]iodomelatonin binding with higher affinity for the human MT1 
receptors. Inhibition constant (Ki) values in the absence of GTP—304 nM 
and 938 nM for UCSF7447 and UCSF3384, respectively—were improved 
by uncoupling the G protein from the receptor by addition of GTP, 
with Ki values improving to 7.5 nM and 63 nM, respectively, support-
ing their status as inverse agonists (Fig. 2a, b, Extended Data Fig. 6 and 
Supplementary Data 3). Both UCSF7447 and UCSF3384 increased the 
basal levels of cAMP—also as expected for inverse agonists—with EC50 
values of 41 nM and 21 nM for human MT1, selectivity for human MT1 over 
human MT2 of 53- and 31-fold, and inverse-agonist efficacies of 62% and 
47% to human MT1, respectively (Fig. 2c, d and Extended Data Fig. 6). The 
third molecule, UCSF4226 was an human MT2-selective agonist with 
an MT2 over MT1 selectivity of 54-fold in 2-[
125I]iodomelatonin binding 
assays and a selectivity of 91-fold in bioluminescence resonance energy 
transfer (BRET) assays; in isoproterenol-stimulated cAMP inhibition 
assays, the agonist had an EC50 of 7.1 nM at human MT2, a value closely 
matched by an EC50 of 6.3 nM in BRET assays (Supplementary Data 4). 
After intravenous administration in mice, the three molecules were 
permeable in the central nervous system, with brain:plasma ratios 
ranging from 1.4 to 3.0. Plasma half-lives ranged from 0.27 to 0.32 h 
(Extended Data Table 3), which is similar to melatonin2. Against mouse 
MT1 and MT2 receptors in vitro, the selectivity of the inverse agonists 
UCSF7447 and UCSF3384 improved compared with the human recep-
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Fig. 2 | Affinity, efficacy and potency of MT1-selective inverse agonists on 
human and mouse MT1 and MT2 receptors. a, b, Affinity (pKi) of the inverse 
agonists UCSF7447 (a) and UCSF3384 (b) compared with 2-[125I]iodomelatonin 
for human MT1 (hMT1), human MT2 (hMT1), mouse MT1 (mMT1) and mouse MT2 
(mMT2) receptors stably expressed in CHO cells. Competitive binding was 
measured in the absence or presence of 100 μM GTP, 1 mM Na2EDTA and 
150 mM NaCl. GTP uncouples G proteins from melatonin receptors, thus 
promoting the inactive conformations of the receptors46 and leading to a 
higher affinity of the receptors for inverse agonists. Therefore, the lighter-
coloured bars show higher binding affinities for the drugs compared with the 
paired darker-coloured bars. Connected symbols represent the pKi values of 
individual determinations run in parallel. Ki values were derived from 
competition binding curves (Supplementary Data 3). Bars represent the mean 
of five independent determinations. Statistical significance between pKi 
averages was calculated by two-tailed paired Student’s t-test (t, d.f. and P values 
are described in the ‘Data analysis’ Methods section, and Supplementary Table 
5). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 compared with the 
corresponding pKi averages values derived in the absence of GTP. c–f, 
Concentration–response curves of human and mouse MT1 and MT2 receptors 
that were transiently expressed in HEK293T cells. Analysis of isoproterenol-
stimulated cAMP production combined with UCSF7447 or UCSF3384 
treatment. Data for UCSF7447 and UCSF3384 were normalized to the 
isoproterenol-stimulated basal activity. Insets, data normalized to the 
maximum effect of UCSF7447 or UCSF3384. c, Human MT1 and MT2 receptors 
treated with UCSF7447. hMT1: pEC50 = 7.39 ± 0.10, Emax = −62 ± 13%, n = 8; hMT2: 
pEC50 = 5.66 ± 0.10, Emax = −84 ± 9%, n = 8; hMT2/hMT1: EC50 = 53. d, Human MT1 
and MT2 receptors treated with UCSF3384. hMT1: pEC50 = 7.68 ± 0.09, 
Emax = −47 ± 12%, n = 13; hMT2: pEC50 = 6.18 ± 0.04, Emax = −153 ± 14%, n = 12; hMT2/
hMT1: EC50 = 31. e, Mouse MT1 and MT2 receptors treated with UCSF7447. mMT1: 
pEC50 = 7.20 ± 0.17, Emax = −56 ± 5%, n = 5; mMT2: pEC50, not determined, Emax, not 
determined, n = 5; mMT2/mMT1: EC50 > 158. f, Mouse MT1 and MT2 receptors 
treated with UCSF3384. mMT1: pEC50 = 7.00 ± 0.22, Emax = −49 ± 3%, n = 5; mMT2: 
pEC50, not determined, Emax, not determined, n = 5; mMT2/mMT1: EC50 > 100. 
Data represent mean ± s.e.m. of the indicated number (n) of biologically 
independent experiments run in triplicate.
for the mouse MT1 receptor compared with the mouse MT2 receptor 
at concentrations of up to 10μM for either compound (Fig. 2e, f and 
Supplementary Data 3). Conversely, whereas the agonist UCSF4226 
lost little activity against the mouse receptor, its selectivity for the 
mouse MT2 receptor was much diminished (Supplementary Data 4). 
Accordingly, we moved forward to in vivo experiments in mice with 
the two selective MT1 inverse agonists.
In vivo pharmacology reveals new MT1 activities
We first examined the in vivo activity of the two MT1-selective inverse 
agonists in a mouse model of re-entrainment. In this ‘east-bound jet-lag’ 
model, mice were subjected to an abrupt 6-h advance in the light–dark 
cycle and treated at the new onset of the dark for three consecutive 
days to assess re-entrainment rate. At 30 μg per mouse, the agonist 
melatonin accelerates re-entrainment to the new cycle, consistent 
with its use in the treatment of east-bound jet-lag in humans (Fig. 3b 
and Extended Data Fig 4b). Conversely, the prototypical non-selective 
antagonist/inverse agonist luzindole (administered at 300 μg per 
mouse) decelerates re-entrainment, measured as the number of days 
to adapt to the new dark onset (Fig. 3b and Extended Data Fig 4e), as 
expected for an inverse agonist31–33. The selective MT1 inverse ago-
nists UCSF7447 and UCSF3384, at a dose of 30 μg per mouse (about 
1 mg kg−1), also decelerated re-entrainment (Fig. 3a, b and Extended 
Data Fig. 4c, d, l), phenocopying luzindole (encouragingly, at a tenfold 
lower dose).
Superficially, the shared effect of decelerating re-entrainment by 
UCSF7447, UCSF3384 (Fig. 3a, b and Extended Data Fig. 4c, d, l) and 
luzindole31,33 might seem expected, as all of the compounds share the 
same function as melatonin receptor antagonists/inverse agonists. 
However, luzindole is MT1/MT2 non-selective, in contrast to UCSF7447 
and UCSF3384. The phenocopying by the compounds of luzindole 
suggests that deceleration of re-entrainment by all three molecules—
slowing jet-lag accommodation—is mediated through the MT1 recep-
tor alone. Supporting this, the effect of UCSF7447 was eliminated in 
MT1-knockout (MT1KO) mice (Fig. 3c and Extended Data Fig. 4h, i, m), 
but not in MT2-knockout (MT2KO) mice, in which its effect was actually 
increased, adding to the deceleration induced by deletion of the MT2 
receptor alone (Fig. 3c and Extended Data Fig 4j, k, n).
The effect of the MT1-selective inverse agonists on the circadian 
phase was even more unexpected. Here, we measured their effects 
on circadian phase by monitoring the running wheel activity onset 
of free-running mice in constant darkness34–36 and administering the 
drugs to the mice at subjective dusk (circadian time 10, CT 10). Both 
inverse agonists induced a phase advance in the onset of the circadian 
wheel running rhythm, an effect that is characteristic of melatonin—the 
endogenous, non-selective agonist—and of non-selective agonist drugs 
such as ramelteon37 and agomelatine9,38 (Fig. 3d and Extended Data 
Fig. 5b–d, g, h). Whereas MT1-selective inverse agonists have few if any 
precedents in vivo, we would have ordinarily expected the opposite 
effect of the agonist39,40—that is, delaying rather than advancing the 
circadian phase. Instead, UCSF7447 advanced the onset of activity by 
approximately 1 h at 0.9 μg per mouse (about 0.03 mg kg−1), an effect 
similar to that of melatonin at its half-maximal effective dose (0.72 μg 
per mouse)34 (Fig. 3d and Extended Data Fig. 5g, h). At a higher dose 
(30 μg per mouse, about 1 mg kg−1), both UCSF7447 and UCSF3384 
advanced the onset of running wheel activity with an amplitude simi-
lar to melatonin34 at this circadian time (Fig. 3d and Extended Data 
Fig. 5b–d). Notably, whereas melatonin and ramelteon advance the 
phase when given at dusk (CT 10), and delay the phase when given at 
dawn (CT 2)35–37,41, UCSF7447 did not affect the circadian phase at dawn 
(Fig. 3f and Extended Data Fig 5r–w) and was only effective at dusk 
(Extended Data Fig. 7a–c).
The phenocopying effect of the non-selective agonist melatonin by 
the MT1-selective inverse agonists in shifting circadian phase motivated 
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Fig. 3 | In vivo, MT1-selective inverse agonists decelerate re-entrainment rate 
and induced a phase advance in circadian activity when administered at 
subjective dusk. a, b, In C3H/HeN wild-type (WT) mice, the inverse agonists 
UCSF3384 and UCSF7447 decelerate re-entrainment rate (a) and increase the 
number of days to re-entrainment after an advance of the dark onset by 6 h in 
the ‘eastbound jet-lag’ paradigm. a, Vehicle (VEH) versus UCSF7447 (7447; 
30 μg per mouse); mixed-effect two-way repeated-measures analysis of 
variance (ANOVA) (treatment × time interaction: F16,735 = 3.39, P = 8.20 × 10
−6). b, 
Vehicle versus melatonin (MLT), UCSF3384 (3384; 30 μg per mouse), UCSF7447 
(30 μg per mouse) or luzindole (LUZ; 300 μg per mouse); one-way ANOVA 
(F4,92 = 16.97, P = 1.86 × 10
−10). c, The inverse agonist UCSF7447 targets MT1 
receptors to increase the number of days to re-entrainment. Vehicle (white) 
versus UCSF7447 (blue; 30 μg per mouse); two-way ANOVA (treatment: 
F1,120 = 24.82, P = 2.14 × 10
−6; genotype: F2,120 = 23.44, P = 2.55 × 10
−9). d, The inverse 
agonists UCSF3384 and UCSF7447 induce a phase advance in the onset of 
running wheel activity in constant dark at CT 10 (dusk), resembling the agonist 
melatonin. Left, vehicle versus melatonin or UCSF7447 (0.9 μg per mouse); one-
way ANOVA (F2,26 = 13.60, P = 9.08 × 10
−5). Centre, vehicle versus melatonin, 
UCSF3384 or UCSF7447 (30 μg per mouse); one-way ANOVA (F3,52 = 32.05, 
P = 7.15 × 10−12). Right, vehicle versus luzindole (300 μg per mouse); two-tailed 
unpaired Student’s t-test (t = 0.92, d.f. = 7, P = 0.39). e, The phase advance of 
wheel activity onset by UCSF7447 is mediated by the MT1 receptor at CT 10 
(dusk). Vehicle (white) versus UCSF7447 (blue; 30 μg per mouse); two-way 
ANOVA (treatment × genotype interaction: F2,49 = 4.46, P = 0.0166). f, The inverse 
agonist UCSF7447, in contrast to melatonin, did not induce a phase delay in 
constant dark at CT 2 (dawn). Vehicle (white) versus UCSF7447 (blue; 30 μg per 
mouse); two-way ANOVA (treatment × genotype interaction: F2,49 = 0.384, 
P = 0.684). In f, one value is not shown due to scale, but is included in the analysis 
(value = 0.91 h). Data are mean ± s.e.m. NS, not significant. *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001 compared with vehicle-treated wild-type mice. 
#P < 0.001; compared with vehicle-treated MT2KO mice. Post-test analyses were 
carried out using Sidak’s (a), Tukey’s (c, e, f) or Dunnet’s (b, d; all P < 0.05) tests. 
Details for all statistical analyses and reporting of n values for each condition 
(depicted as scatter plots where appropriate) can be found in the Methods, 
‘Statistics and reproducibility’ section and Supplementary Table 4. All mice 
were treated with different compounds using subcutaneous injections.
us to investigate the mechanism of action and the role of off-target 
effects. Accordingly, both molecules, as well as the human MT2-selective 
agonist UCSF4226, were tested against a panel of common off-target 
receptors (Supplementary Data 1). In radioligand competition assays, 
no activity was seen up to a concentration of 10 μM for the new ligands. 
Against a panel of 318 G-protein-coupled receptors (GPCRs), activity 
was observed for only seven receptors when screened at a single con-
centration, activity against none of these seven receptors was replicated 
in full concentration–response assays (Supplementary Data 2).
Consistent with activity mediated by the MT1 receptor, the advance 
in the onset of running wheel activity at dusk (CT 10) by UCSF7447 
was eliminated in MT1KO mice but not in MT2KO mice (Fig. 3e and 
Extended Data Fig. 5l–q). These observations suggest that the MT1-
selective inverse agonists UCSF7447 and UCSF3384 are not only potent, 
with effects on phase shift for UCSF7447 at 0.9 μg per mouse (about 
0.03 mg kg−1) (Fig. 3d) and efficacies that resemble the long-established 
reagent luzindole in the jet-lag model at tenfold lower doses, but also 
that their unexpected activity in the circadian phase paradigm is medi-
ated by the MT1 receptor. We note that the lack of precedence for this 
behaviour reflects a lack of MT1-selective inverse agonists to investigate 
this effect, something that is addressed by this study.
Discussion
We discovered, in a large library docking screen, multiple, previously 
undescribed chemotypes for melatonin receptors (Fig. 1) that have 
new signalling mechanisms and pharmacology. Three features of this 
study are worth emphasizing. First, docking a library of more than 
150 million diverse, make-on-demand molecules found ligands that 
are topologically unrelated to known melatonin receptor ligands, with 
picomolar and nanomolar activity on the melatonin receptors. Second, 
the chemical novelty of these molecules translated functionally, confer-
ring melatonin-receptor-type selectivity. Whereas the deceleration of 
re-entrainment ( jet-lag model) by these inverse agonists resembled that 
of the classic non-selective antagonist/inverse agonist luzindole, their 
high selectivity for the MT1 receptor, and the chemical–genetic epistasis 
in the MT1KO mouse, convincingly implicates the MT1 receptor in this 
response. Unexpectedly, the inverse agonists conferred an agonist-
like effect in circadian phase-shift experiments when administered at 
dusk, perhaps suggesting previously unknown signalling control for 
the MT1 receptor in the suprachiasmatic nucleus of the hypothalamus, 
which has known time-of-day-dependent receptor-mediated signalling 
pathways42. Third, these are, to our knowledge, the first MT1-selective 
inverse agonists that are active in vivo, with efficacy at doses as low as 
0.9 μg per mouse in the circadian phase shift paradigm. Their efficacy 
in modulating time-dependent circadian entrainment supports their 
potential as lead molecules for the design of therapeutics for conditions 
and diseases that are affected by alterations in the circadian phase5–7,43.
Certain caveats should be noted. Although we sought MT1-selective 
ligands, we found ligands for both melatonin receptor types, reflecting 
their conserved orthosteric sites. Indeed, rather than adopting a struc-
ture-based strategy for type selectivity, we simply focused on chemical 
novelty among the high-ranking docked molecules15,17. Although the 
39% docking hit rate was high, and the hits were potent, this probably 
reflects a site that is unusually well-suited to ligand binding: it is small, 
solvent-occluded and largely hydrophobic. These high hit rates and 
potencies may not always translate to other targets44,45.
The key observations of this work should nevertheless be clear. From 
a structure-based screen of a diverse, 150 million compound virtual 
library sprang 15 new chemical scaffolds, topologically unrelated to 
known melatonin receptor ligands, synthesized de novo for this project. 
From their chemical novelty emerged previously undescribed activi-
ties, including inverse agonists and ligands with melatonin-receptor-
type selectivity. The potency, brain exposure and selectivity of these 
ligands enable the disentanglement of the physiological role of the 
MT1 receptor. Accordingly, we are making the MT1-selective inverse 
agonist UCSF7447, and the human MT2 selective agonist UCSF4226, 
openly available to the community as probe pairs together with a close 
analogue that has no measurable activity on the melatonin receptors 
(Extended Data Table 4). We note that only a small fraction of even the 
highest-ranking chemotypes from the docking screen were tested here; 
it is likely that hundreds-of-thousands of melatonin receptor ligands, 
representing tens-of-thousands of new chemotypes15, remain to be 
discovered from the make-on-demand library, which continues to grow 
(http://zinc15.docking.org). This study suggests that not only potent 
ligands may be revealed by docking such a library, but also that the 
new chemotypes explored can illuminate new in vivo pharmacology.
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Methods
Molecular docking
The MT1 receptor with nine thermostabilizing point mutations, as 
determined crystallographically13, was used in the docking calcula-
tions. To prepare the structure for docking, atoms of the co-crystallized 
ligand, 2-phenylmelatonin, were used to seed the matching sphere 
calculation in the orthosteric site; these spheres represent favourable 
positions for individual ligand atoms to dock; 45 spheres were used 
in total. DOCK3.7 orients flexibases of pre-calculated ligand confor-
mations into the orthosteric site by overlaying atoms of each library 
molecule onto these matching spheres. The receptor structure was 
protonated by REDUCE47 and assigned AMBER united atom charges48. 
For residues N1624.60 and Q181ECL2, the partial atomic charges of the 
side chain amide were increased without changing the net charge of 
the residue, as described previously49. The volume of the low protein 
dielectric, which defines the boundary between solute and solvent 
in Poisson–Boltzmann electrostatic calculations, was extended out 
1.9 Å from the protein surface using spheres calculated by SPHGEN. 
Scoring grids were pre-calculated using CHEMGRID for AMBER van der 
Waals potential, QNIFFT50 for Poisson–Boltzmann-based electrostatic 
potentials, and SOLVMAP51 for ligand desolvation.
The resulting potential grids and ligand-matching parameters were 
evaluated for their ability to enrich known MT1 ligands over property-
matched decoys. Decoys share the same physical properties as known 
ligands but are topologically dissimilar and are therefore unlikely to 
bind to the receptors. We extracted 31 known MT1 melatonin receptor 
ligands—both agonists and antagonists—from the IUPHAR database52 
and 1,550 property-matched decoys were generated using the DUD-E 
pipeline. Docking success was judged based on the ability to enrich the 
known ligands over the decoys by docking rank, using adjusted logAUC 
values, as is widely done in the field. We also ensured that molecules 
with extreme physical properties were not enriched, as can happen 
when only counter-screening against property-matched decoys. In 
particular, we wanted to ensure that neutral molecules were enriched 
over charged ones. The docking parameters were also judged on how 
well they reproduced the expected binding modes of the known ligands 
as well as their ability to form hydrogen bonds with N1624.60 and Q181ECL2.
The ‘lead-like’ subset of ZINC15 (http://zinc15.docking.org), charac-
terized by favourable physical properties (for example, with calculated 
octanol-water partition coefficients (cLopP) ≤ 3.5 and with molecular 
mass ≤ 350 Da), was then docked against the MT1 orthosteric site
21, using 
DOCK3.7. This library contained more than 150 million molecules, most 
of which were make-on-demand compounds from the Enamine REAL 
set15. Of these, more than 135 million molecules successfully docked, 
with more than 36 million receiving a favourable score (<0 kcal mol−1). 
An average of 3,445 orientations was calculated for each, and for each 
orientation, an average of 485 conformations was sampled. A simplex 
minimizer was used for rigid-body minimization on the best-scored 
pose for each ligand. Overall, about 72 trillion complexes were sam-
pled and scored. The calculation time was 45,020 core hours, or 1.25 
calendar days on 1,500 cores.
To reduce the redundancy of the best-ranking docked molecules, 
the top 300,000 ranked molecules were clustered by ECFP4-based 
Tanimoto coefficient (Tc) of 0.5, and the best-scoring member was used 
to represent the cluster. The resulting 65,323 clusters were filtered for 
novelty by calculating the ECFP4-based Tanimoto coefficient against 
>1,100 MT1 and MT2 receptor ligands from the CHEMBL23
22 database. 
Molecules with Tanimoto coefficients of ≥0.38 to known MT1/MT2 
ligands were not further pursued.
After filtering for novelty, the docked poses of the best-scoring 
members of each cluster were filtered by the proximity of their polar 
moieties to N1624.60 or Q181ECL2, and manually inspected for favourable 
geometry and interactions. Of the best-scoring molecules prioritized 
in this way, all members of its cluster within the top 300,000 molecules 
were also inspected, and sometimes one of these was chosen if they 
exhibited more favourable poses or chemical properties. Finally, 
40 compounds were chosen for testing, 38 of which were success-
fully synthesized. To our knowledge, none of these compounds has 
been previously available and we are unaware of reports of them being 
previously synthesized.
Make-on-demand synthesis
Compounds were synthesized using 72,000 qualified in stock build-
ing blocks and 130 well-characterized, two-component reactions at 
Enamine. Previously, molecules have been synthesized in 3–4 weeks 
with an 85% fulfilment rate; in this project the delivery time was 
6 weeks, but with a 95% fulfilment rate for the 40 molecules that were 
prioritized from the initial docking screen. Each reaction is tested for 
conditions including temperatures, completion time and mixing53. 
Typically, compounds were made in parallel by combining reagents 
and solvents in a single vial in the appropriate conditions to allow the 
reaction to proceed to completion. The product-containing vial is 
filtered by centrifugation into a second vial to remove the precipitate 
and the solvent is evaporated under reduced pressure; the product is 
then purified by high-performance liquid chromatography. Identity 
and purity are assessed by liquid chromatography–mass spectrometry 
(LC–MS) and, as appropriate, 1H NMR (Supplementary Table 2, Sup-
plementary Data 7). All compounds were shipped with a purity of 90% 
or better, and the three main compounds UCSF7447, UCSF3384 and 
UCSF4226 were independently confirmed to be ≥95% pure by LC–MS 
in secondary confirmation analyses at a second laboratory (Supple-
mentary Data 5). Details regarding the synthesis and analyses of the 
compounds are provided in Supplementary Data 6, 7.
Structure-based ligand optimization
After experimental testing (see ‘cAMP assay’), 12 of the 15 active ligands 
from docking were prioritized for optimization, representing a range 
of activities and type selectivity (Extended Data Table 2 and Supple-
mentary Table 1). Several thousand analogues of these ligands—each 
bearing the same scaffold as the parent molecule and with a Tanimoto 
coefficient of <0.38 to annotated melatonin receptor ligands—were 
selected from the ZINC database and docked to the MT1 binding site, 
again using DOCK3.7. The resulting docked poses were manually evalu-
ated for interactions with N1624.60 or Q181ECL2, and 132 analogues were 
selected for de novo synthesis at Enamine, in two iterations. Of these, 
131 were successfully synthesized, a >99% fulfilment rate.
Cell culture
HEK293T cells were maintained with complete Dulbecco’s modified 
Eagle’s medium (DMEM), supplemented with 10% fetal bovine serum 
(FBS), 2 mM l-glutamine, 100 U ml−1 penicillin G and 100 μg ml−1 strep-
tomycin. Cells were maintained at 37 °C in the presence of 5% CO2.
Tango arrestin recruitment assay
MT1 and MT2 Tango constructs were designed and assays were per-
formed as previously described54. In brief, HTLA cells stably expressing 
TEV-protease-fused β-arrestin (provided by R. Axel) and a tTA-depend-
ent luciferase reporter gene were transfected with the MT1 or MT2 Tango 
construct. The next day, transfected cells were seeded into poly-l-lysine- 
coated 384-well white clear-bottom cell-culture plates with DMEM 
containing 1% dialysed FBS at a density of 20,000 cells per well in 40 μl 
for another 6 h. The drug-containing solution was prepared in the same 
medium as used for cell plating at 5× final concentration and 10 μl per 
well was added for overnight incubation. The next day, medium and 
drug solutions were discarded and wells were loaded with 20 μl per 
well of Bright-Glo reagent (Promega). Plates were incubated for 20 min 
in the dark, after which luminescence was counted for the cell using a 
SpectraMax luminescence reader (Molecular Device). Data were ana-
lysed using GraphPad Prism 6.0 (GraphPad Software).
cAMP assay
MT1 and MT2 receptors were tested using split luciferase-based GloSen-
sor cAMP biosensor technology (Promega). HEK293T cells were plated 
in 15-cm cell-culture dishes (at around 50% cell confluency) with DMEM 
supplemented with 10% dialysed FBS, 2 mM l-glutamine, 100 U ml−1 
penicillin G and 100 μg ml−1 streptomycin for 4–6 h. Then, cells were 
co-transfected with 8 μg of constructs encoding either MT1 or MT2 
(de-Tango-ized constructs) and 8 μg of Glosensor DNA. The next day, 
transfected cells were seeded into poly-l-lysine-coated 384-well white 
clear-bottom cell-culture plates with complete DMEM supplemented 
with 1% dialysed FBS at a density of 20,000 cells per well for another 
24 h. The subsequent day, cell medium was discarded and wells were 
loaded with 20 μl of assay buffer (1× HBSS, 20 mM HEPES, pH 7.4, 0.1% 
BSA). To measure agonist activity of MT1 or MT2 receptor, 10 μl of test 
compound solution at 3× final concentration was added for 15 min 
followed by addition of 10 μl of luciferin/isoproterenol mixture (at 
a final concentration of 4 mM and 200 nM, respectively) for another 
15 min for luminescence quantification. Then, plates were counted 
using a SpectraMax luminescence reader (Molecular Device). Data 
were analysed using GraphPad Prism 8.
Calculation of log(Emax/EC50) and quantification of ligand bias
The Δlog(Emax/EC50) was calculated with melatonin as a reference ago-
nist for G protein and β-arrestin pathway, and the ΔΔlog(Emax/EC50) was 
calculated between two pathways for each ligand55, as were correspond-
ing bias plots56. The bias factor is unitless and defined as 10 EΔΔ log( /EC )max 50
.
GPCRome counterscreen
Screening of compounds in the PRESTO-Tango GPCRome was accom-
plished as previously described54 with several modifications. First, 
HTLA cells were plated in DMEM with 10% FBS and 10 U ml−1 penicil-
lin–streptomycin. Next, the cells were transfected using an in-plate PEI 
method57. PRESTO-Tango receptor DNAs were resuspended in OptiMEM 
and hybridized with PEI before dilution and distribution into 384-well 
plates and subsequent addition to cells. After overnight incubation, 
drugs were added to cells without replacement of the medium. The 
remaining steps of the PRESTO-Tango protocol were followed as previ-
ously described. For those six receptors for which activity was reduced 
to less than 0.5-fold of basal levels of relative luminescence units or for 
the one receptor for which basal signalling was increased greater than 
threefold of basal levels, assays were repeated as a full dose–response 
assay. Activity for none of the seven could be confirmed, and we dis-
count the apparent activity seen in the single-point assay.
Inhibition screen
Binding assays were performed by the NIMH Psychoactive Drug Screen-
ing program as described previously58. Detailed binding assay pro-
tocols are available at: https://pdspdb.unc.edu/pdspWeb/content/
UNC-CH%20Protocol%20Book.pdf.
BRET recruitment assay
To measure the dissociation of labelled Gαi3 from the labelled Gβγ com-
plex after the receptor stimulation, HEK293T cells were co-transfected 
in a 1:1:1:1 ratio of Gαi3-RLuc, Gβ3, GFP2-Gγ9, and human MT1or MT2 
(de-Tango-ized constructs), respectively. After 24 h, transfected cells 
were plated in poly-l-lysine-coated 96-well white clear-bottom cell-
culture plates with DMEM containing 1% dialysed FBS, 100 U ml−1 penicil-
lin G and 100 μg ml−1 streptomycin at a density of 40,000 cells in 200 μl 
per well and incubated overnight. The following day, the medium was 
removed and cells were washed once with 100 μl of assay buffer (1× 
HBSS, 20 mM HEPES, pH 7.4, 0.1% BSA). Then 60 μl of assay buffer was 
loaded per well followed by addition of 10 μl of the RLuc substrate, 
coelenterazine 400a (Nanolight), at 5 μM final concentration for 5 min. 
Drug stimulation was performed with the addition of 30 μl of 3× drug 
dilution of melatonin or UCSF4226 in assay buffer supplemented with 
0.01% (w/v) ascorbic acid per well and incubated at room temperature 
for another 5 min. Both luminescence (400 nm) and fluorescent GFP2 
emission (515 nm) were read for the plate for 1 s per well using Mithras 
LB940. The ratio of GFP2/RLuc was calculated per well and analysed 
using ‘log (agonist) vs. response’ in GraphPad Prism 8.
Radioligand binding
Reagents and ligands. 2-[125I]Iodomelatonin (SA: 2,200  Ci, 
81.4  TBq  mmol−1) was purchased from Perkin Elmer. Guanosine 
5′-triphosphate sodium salt hydrate (GTP), melatonin and all other 
chemicals and reagents were obtained from Sigma-Aldrich.
Compound preparation. For receptor binding studies, UCSF7447 
was dissolved in 50% DMSO/50% ethanol as a 13 mM stock solution, 
diluted 1/10 in 100% ethanol then 1/10 again in 50% ethanol/50% Tris-
HCl buffer, pH 7.4 25 °C. Both UCSF3384 and UCSF4226 were dissolved 
in 100% ethanol as 13 mM stock solutions and then diluted 1/10 in 50% 
ethanol/50% Tris-HCl buffer, pH 7.4. Further dilutions were done in the 
same Tris-HCl buffer.
2-[125I]Iodomelatonin competition binding. CHO cells stably express-
ing Flag-tagged recombinant human or mouse MT1 or MT2 melatonin 
receptors were grown in culture as monolayers in Ham’s F12 medium 
supplemented with fetal calf serum (10%), penicillin (1%; 
10,000 I.U. ml−1)–streptomycin (5%; 10,000 μg ml−1) in CO2 at 37 °C as 
described. Cells were grown for 4 days to 90–95% confluence, then 
washed with PBS (potassium phosphate buffer, 10 mM, pH 7.4), detached 
with PBS containing 0.25 M sucrose and 1 mM EDTA, and pelleted by cen-
trifugation (1,700g, 5 min) as described59. Cell pellets were suspended 
and homogenized in control buffer (50 mM Tris-HCl, 10 mM MgCl2; 
pH 7.4 at 25 °C) and washed twice by centrifugation (17,000g, 15 min) in 
control or inactive conformation buffer (50 mM Tris-HCl, 10 mM MgCl2, 
100 μM GTP, 1 mM EDTA-Na2, 150 mM NaCl, pH 7.4 at 25 °C) as described
59. 
2-[125I]Iodomelatonin binding affinity was determined on membranes 
from CHO cells expressing human MT1 (9.6 ± 0.3 μg protein per assay; 
Bmax = 1,154 ± 38 fmol mg
−1 protein; n = 3), human MT2 (15 ± 1 μg protein per 
assay; Bmax = 352 ± 19 fmol mg
−1 protein; n = 3), mouse MT1 (6.0 ± 0.022 μg 
protein per assay; Bmax = 1,705 ± 337 fmol mg
−1 protein; n = 3) or mouse 
MT2 (6.4 ± 0.7 μg protein per assay; Bmax = 725 ± 93 fmol mg
−1 protein; 
n = 3). Ligand competition (10 pM to 100 μM) for 2-[125I]iodomelatonin 
(104 ± 2 pM, n = 30) binding was performed in control or inactive con-
formation buffer in a total volume of 0.26 ml as described59. Assays were 
incubated for 1 h at 25 °C. Bound radioligand was separated from free 
by rapid vacuum filtration using glass microfibre filters (Whatman, 
Krackeler Scientific) saturated in 0.5% polyethylenimine solution. Total 
radioactivity bound to the filters was determined on a gamma counter59.
Data analysis. Ki values were calculated from IC50 values using Graph-
Pad Prism 8.0 according to the Cheng–Prusoff equation60: Ki = IC50/
(1 + [L]/Kd) where L is the concentration of radioligand, Kd is the dissocia-
tion constant of 2-[125I]iodomelatonin in control or inactive conforma-
tion buffer for the human MT1 (control Kd = 116 pM; inactive Kd = 280 pM), 
human MT2 (control Kd = 80 ± 13 pM; GTP Kd = 461 ± 159 pM) and mouse 
MT1 (control Kd = 87 ± 6 pM; GTP Kd = 201 + 67 pM) receptors (n = 3). 
Affinity shifts induced by G-protein uncoupling were measured by 
subtracting pKi(inactive) from pKi(control) (ΔpKi) and normalization to the 
ΔpKi of melatonin (CHO cells expressing human MT1, 1.19; CHO cells 
expressing human MT2, 0.41). Affinity shifts or lack thereof with G-
protein uncoupling indicate apparent efficacy46 as ligands are classified 
as agonists (ΔpKi percentage of melatonin >20%), antagonists (ΔpKi 
percentage of melatonin <20%, >−20%) or inverse agonists (ΔpKi per-
centage of melatonin <−20%) accordingly. Individual data points were 
excluded from cell-based analyses when meeting the exclusion criteria 
of the outliers Grubbs test. Data shown in Fig. 2a, b were analysed by 
two-tailed paired Student’s t-test (Supplementary Table 5).
In vivo methods
Animals and housing. Male and female C3H/HeN wild-type, MT1KO, 
and MT2KO mice (average age, 6.28 months) used in this study were 
raised in our breeding colony at University at Buffalo. C3H/HeN mice 
homozygous for the MT1 and MT2 melatonin receptor gene deletion and 
their wild-type controls were generated from breeding pairs donated 
by S. M. Reppert (University of Massachusetts Medical School) and 
backcrossed with C3H/HeN mice (Harlan, now Envigo) for at least seven 
generations as described previously61. Genotype was confirmed using 
tail samples at the end of each experiment and was verified periodically 
during the tenure of the colony. The strains of mice in our breeding 
colony were re-derived periodically by backcrossing with wild-type 
mice to reduce genetic drift.
Mice were group-housed (3–5 per cage) with corncob bedding in poly-
carbonate translucent cages (30 cm × 19 cm) and maintained in a 14/10 
light–dark cycle (Zeitgeber time 0 (ZT 0) corresponds to lights on and 
ZT 14 to lights off) in temperature- and humidity-controlled rooms with 
ad libitum access to food and water in the Laboratory Animal Facility at 
the University at Buffalo. Light levels were 200–300 lx at the level of the 
cage. Treatments and animal care performed in the dark were carried 
out under a dim red safelight (15 W, Kodak 1A filter) with illuminance 
of less than 3 lx as described previously35. All experimental procedures 
using mice were conducted in accordance with guidelines set forth 
by the National Institutes of Health and approved by the University at 
Buffalo Institutional Animal Care and Use Committee.
Circadian rhythm measurements. Circadian rhythm phase was de-
termined for each mouse using the onset of running wheel activity 
defined as CT 12 (onset of wheel activity). Running wheel activity was 
measured continuously by magnetic microswitches that detect wheel 
revolutions using a computer equipped with ClockLab data-collection 
software (Actimetrics). All actigraphy data were visualized and ana-
lysed using ClockLab and MATLAB software. All mice were individually 
housed in cages (33 cm × 15 cm) equipped with running wheels in light-
tight ventilated cabinets with controlled temperature and light–dark 
cycles (Phenome Technologies). Male and female mice were housed in 
separate cabinets for all experiments.
Phase shift. Changes in circadian phase induced by vehicle or drugs 
administered at various circadian times were assessed in wild-type, 
MT1KO and MT2KO male and female C3H/HeN mice (3–8 months of age) 
using methods and protocols that have been previously described34,35. 
Following a period of 14 days in a light–dark cycle, mice were placed in 
constant dark beginning at ZT 12 (dark onset) (ZT 0, lights on). Mice 
were kept in constant dark (2–3 weeks) until a stable free-running phase 
of running wheel activity rhythm onset was established. Circadian times 
of treatment were predicted from best fit lines of running wheel activ-
ity onsets for running either before (7–14 days) and after (7–14 days) 
treatment. Treatment times were within a 2-h window at CT 2 (CT 1–3), 
CT 6 (CT 5–7) or CT 10 (CT 9–11). Mice were treated (0.1 ml per mouse, 
subcutaneously) with vehicle (30% ethanol saline, subcutaneously) 
or drugs (melatonin, UCSF3384 or UCSF7447, at 0.9 μg and 30 μg per 
mouse or luzindole at 300 μg per mouse in vehicle) for 3 consecutive 
days at the appropriate circadian time under dim red light. Vehicle or 
drug treatments were repeated for 3 consecutive days at the selected 
circadian time following the three-pulse treatment protocol described 
previously35. Phase shifts were quantified using the best fit lines for on-
sets of activity during pre- and post-treatment periods. Differences are 
characterized as phase delays (pre-treatment ahead of post-treatment 
best fit line onset) or phase advances (post-treatment ahead of pre-
treatment best fit line onset) of running wheel activity onset rhythms.
Re-entrainment experiments. Male and female C3H/HeN wild-type, 
MT1KO and MT2KO mice (3–6 months of age) were maintained under a 
12:12 light–dark cycle for at least 2 weeks before experimental manipula-
tions to enable stable entrainment to dark onset before advance of the 
light–dark cycle. Actigraphy data were recorded as described above and 
all experimental protocols were performed as described previously62. 
On the first day of treatment, the dark onset was advanced 6 h. This 
resulted in a short night. Mice were treated (0.1 ml per mouse, subcu-
taneously) with vehicle (30% ethanol/70% saline) or drugs (melatonin, 
UCSF3384 or UCSF7447 at 30 μg per mouse, or luzindole 300μg per 
mouse, in vehicle) for three consecutive days 10–30 min before the 
new dark onset. After treatment, mice were given 14–20 days to re-
entrain the onset of running wheel activity to the new dark onset. Using 
exported running wheel activity onsets from actograms, the number 
of onset hours advanced each day was determined by subtracting this 
value each day from the average onset of stably entrained running wheel 
activity for 3 days before treatment for each mouse. Furthermore, 
using the data from this calculation combined with visualization of 
actograms, the number of days to reach stable re-entrainment was 
determined for each mouse.
In vivo compound preparation. All compounds were administered 
in fixed doses of either 0.9 μg or 30 μg subcutaneously in a volume of 
0.1 ml per mouse, which are equivalent to doses of 0.03 or 1 mg kg−1 for 
a 30 g mouse, respectively. Vehicle was 30% ethanol/70% saline for all 
doses. Melatonin, UCSF7447 and UCSF3384 were prepared as stock 
solutions of 3 mg ml−1 (100% ethanol) using sonication and vortexing 
to ensure that each drug was dissolved. Subsequently, stock solutions 
were diluted to 0.3 mg ml−1 (30 μg per 0.1 ml injection) or 0.009 mg ml−1 
(0.9 μg per 0.1 ml injection) in vehicle. Luzindole was prepared similarly, 
except the starting stock solution was 30 mg ml−1 in 100% ethanol and 
it was administered from a solution of 3 mg ml−1 (300 μg per 0.1 ml 
injection) in vehicle. Treatment dilutions were prepared just before 
use under sonication with intermittent vortexing between steps and 
used within 5 min of preparation.
Biostatistics and reproducibility. All statistical analyses as described 
in further detail for each experiment were conducted using GraphPad 
Prism 8. For phase shift and re-entrainment experiments, we deter-
mined statistical power a priori (error probability, α = 0.05) based on 
data for a known effect size for melatonin in these paradigms (G-power 
3.0.10)34,62. Individual actograms of wheel running activity were 
excluded from analysis based on the exclusion criteria described below, 
which was completed by at least two individuals who were blind to 
treatment before data analysis was started. For re-entrainment acto-
grams exclusion criteria included: (1) low running, sporadic activity, 
substantial missing wheel activity data and/or lack of entrainment 
before treatment; (2) entrainment of running activity more than 1 h be-
fore or after the ‘old’ or ‘new’ dark onset; (3) re-entrainment to the new 
dark onset before administration of the third injection (entrainment 
to injection). For phase-shift actograms exclusion criteria included: 
(1) low running, sporadic activity, missing wheel activity data and/
or lack of free running activity rhythms; (2) tau change >0.3 h; (3) at 
least two out of three injections occurred outside of the target prede-
termined time range for treatment (CT 1–3, 5–7, 10–12). All datasets 
were visualized for normality using QQ plots of predicted versus actual
residuals. Actigraphy data were generated for visualization blind to 
treatment before the quantification and statistical analysis stages. 
Comparisons for Fig. 3a and Extended Data Fig. 4l, m, n were made by 
mixed-effect two-way repeated-measures ANOVA (treatment × time) 
with Sidak’s post hoc test (P < 0.05). Number of days to re-entrainment 
was compared using one-way ANOVA or two-way ANOVA for Fig. 3b, c 
with a Dunnet’s or Tukey’s post hoc test (P < 0.05), respectively. Group 
comparisons for phase shift in Fig. 3d (left and centre) and Extended 
Data Fig. 7a–c were made by one-way ANOVA (P < 0.05) comparing hours 
shifted of circadian running wheel activity rhythm onsets (Fig. 3d (left), 
three groups: vehicle, melatonin and UCSF7447; Fig. 3d (centre), four 
groups vehicle, melatonin, UCSF7447 and UCSF3384; Extended Data 
Fig. 7a–c, four groups: vehicle, melatonin, UCSF7447 and luzindole) 
accompanied by post hoc analyses using Dunnet’s test to determine 
individual group differences compared with vehicle (P < 0.05). Compari-
sons in Fig. 3d (right) between vehicle and luzindole were made using 
a two-tailed unpaired Student’s t-test (P < 0.05). Data in Fig. 3e, f were 
compared using a two-way ANOVA (3 × 2: genotype × treatment) with 
Tukey’s post hoc analyses (P < 0.05). P values and values for statistical 
analyses are included in the figure legends or listed in Supplementary 
Table 4. Either the overall interaction or the main effects are reported 
and interpreted using two-way ANOVAs as appropriate for assumptions 
of each dataset. No sex differences in treatment effects were evident 
in any dataset when assessed by two-way ANOVA or three-way ANOVA 
where appropriate; therefore, data were pooled between male and 
female mice for the described analyses. The n values represent the 
number of individual mice per condition or independent biological 
replicates in each experiment. Each dataset represents 2–4 independ-
ent experiments. The n value for each in vivo experiment is listed below 
(n values with an asterisk indicate values for multiple comparisons 
ranging from 1 to 2 values less depending on the day of comparison 
due to missing onset data that are accounted for in statistical models 
as appropriate). See statistical parameters in Supplementary Table 4.
Figure 3a, vehicle (n = 28 mice*) versus UCSF7447 (n = 21 mice*). 
Figure 3b, vehicle (n = 28) versus melatonin (n = 21), UCSF7447 (n = 21), 
UCSF3384 (n = 16) or luzindole (n = 11). Figure 3c, wild-type (n = 28 
vehicle; n = 21 UCSF7447), MT1KO (n = 16 vehicle; n = 16 UCSF7447) and 
MT2KO (n = 20 vehicle; n = 25 UCSF7447). Figure 3d, left: vehicle (n = 8) 
versus melatonin (n = 8) or UCSF7447 (n = 13); centre: vehicle (n = 15) 
versus melatonin (n = 10), UCSF3384 (n = 16) or UCSF7447 (n = 15); right: 
vehicle (n = 6) versus luzindole (n = 3). Figure 3e, wild-type (n = 9 vehicle; 
n = 10 UCSF7447), MT1KO (n = 8 vehicle; n = 8 UCSF7447) and MT2KO 
(n = 11 vehicle; n = 9 UCSF7447). Figure 3f, wild-type (n = 8 vehicle; n = 8 
UCSF7447), MT1KO (n = 6 vehicle; n = 7 UCSF7447) and MT2-KO (n = 10 
vehicle; n = 13 UCSF7447).
Extended Data Figure 4l, C3H/HeN wild-type: vehicle (n = 28 mice*) 
versus UCSF3384 (n = 16 mice*). Extended Data Figure 4m, C3H/HeN 
MT1KO: vehicle (n = 16 mice*) versus UCSF7447 (n = 16 mice*). Extended 
Data Figure 4n, C3H/HeN MT2KO: vehicle (n = 21 mice*) versus UCSF7447 
(n = 25 mice).
Extended Data Figure 7a, CT 2: vehicle (n = 3), melatonin (n = 3), luz-
indole (n = 6) and UCSF7447 (n = 3). Extended Data Figure 7b, CT 6: 
vehicle (n = 8), melatonin (n = 4), luzindole (n = 9) and UCSF7447 (n = 9). 
Extended Data Figure 7c, CT 10: vehicle (n = 6), melatonin (n = 8), luz-
indole (n = 3) and UCSF7447 (n = 4)
Pharmacokinetics. Pharmacokinetic experiments were performed by 
Sai Life Sciences. Plasma pharmacokinetics and brain distribution for 
UCSF7447, UCSF3384 and UCSF4226 were investigated following a 
single intravenous dose of 2 mg kg−1 in 9 male C57BL/6 mice. Each com-
pound was formulated in 5% N-methyl-pyrrolidone, 5% solutol HS-15 and 
90% normal saline. Blood samples (approximately 60 μl from each of 
three mice) were collected under light isoflurane anaesthesia from the 
retro-orbital plexus at 0.08, 0.25, 0.5, 1, 2, 4, 8, 12 and 24 h. Immediately 
after collection, plasma was obtained by centrifugation and stored at 
−70 °C until analysis. For blood collected at 0.5, 4 and 24 h, animals 
were euthanized with excess CO2 asphyxiation and brain samples were 
collected and homogenized in ice-cold phosphate-buffered saline 
(pH 7.4). Total homogenate volume was three times the brain weight.
All samples were processed for analysis by protein precipitation using 
acetonitrile and analysed using a fit-for-purpose LC–MS/MS method 
(lower limit of quantification, 2.01 ng ml−1 for plasma and 6.03 ng g−1 
for brain for UCSF7447, 5.01 ng ml−1 for plasma and 3.00 ng g−1 for 
brain for UCSF3384, 1.01 ng ml−1 for plasma and 6.09 ng g−1 for brain 
for UCSF4226). The non-compartmental analysis module in Phoenix 
WinNonlin (v.7.0) was used to assess the pharmacokinetic parameters. 
The maximum concentration (Cmax) and time to reach the maximum 
concentration (Tmax) were measured. The areas under the concentration 
time curve (AUClast and AUCinf) and elimination half-life were calculated 
by the linear trapezoidal rule. The terminal elimination rate constant, 
ke, was determined by regression analysis of the linear terminal portion 
of the log plasma concentration–time curve. The terminal half-life (T1/2) 
was estimated as 0.693/ke.
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
Data availability
Probe pairs (two similar ligands with and without activity) of inverse 
agonists selective for MT1 and agonists selective for hMT2 are available 
by arrangement with Sigma (Extended Data Fig. 3). The identities of 
the compounds docked in this study are freely available from the ZINC 
database (http://zinc15.docking.org) and active compounds may be 
purchased from Enamine. Raw data are available for Fig. 1, Extended 
Data Tables 1, 2 and Extended Data Figs. 1, 2 in Supplementary Tables 1 
(MT1 and MT2 affinities, MT1 DOCK energies and ranks) and 2 (com-
pound purity information). Bias information for Extended Data Fig. 3 is 
included in Supplementary Table 3. For Fig. 2, data from the GPCRome 
screens, concentration–response curves, and competition binding 
and LC–MS experiments are included in Supplementary Data 1–5 and 
synthesis routes and spectra of compounds in Supplementary Data 6, 
7. Further data for Fig. 3 are included in Extended Data Figs. 4, 5, 7 and 
Supplementary Table 4. Raw data values and transformed data for 
in vitro cell-based assays as well as in vivo data for phase shift and 
re-entrainment are available for Figs. 2, 3 and Extended Data Figs. 4 
(re-entrainment), 5 (phase shift), 6, 7a–c.
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DOCK3.7 is freely available for non-commercial research (http://dock.
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is freely available at http://zinc15.docking.org/.
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Extended Data Fig. 1 | Concentration–response curves of the initial 15 
compounds in cAMP assays. a–f, Inhibition of isoproterenol-stimulated cAMP 
mediated by hMT1 (a, c, e) or hMT2 (b, d, f) in HEK293T cells by melatonin and 
the 15 initial compounds. Data are normalized to the melatonin response. The 
15 initial compounds were split into three graphs for clarity, melatonin 
response curves are the same across graphs in a, c, e and b, d, f. Data are 
mean ± s.e.m. of four biologically independent experiments (n = 4) run in 
triplicate, unless otherwise indicated, in which case the number of biologically 
independent experiments is indicated in parentheses next to the compound 
name.
Extended Data Fig. 2 | Concentration–response curves of notable analogues 
based on initial hits in cAMP assays. a–f, Inhibition of isoproterenol-
stimulated cAMP mediated by hMT1 (a, c, e) or hMT2 (b, d, f) in HEK293T cells by 
melatonin and select analogues. Data are normalized to the melatonin 
response. The compounds were split into three graphs for clarity, melatonin 
response curves are the same across graphs in a, c, e and b, d, f. Data are 
mean ± s.e.m. of four biologically independent experiments (n = 4) run in 
triplicate, unless otherwise indicated, in which case the number of biologically 
independent experiments is indicated in parentheses next to the compound 
name.
Extended Data Fig. 3 | Small changes in the ligand structure have large 
effects on the activity and selectivity of the melatonin receptor. a, Docked 
pose of ZINC151209032, an MT1-selective direct-docking hit. b, Docked pose of 
ZINC497291360, a close analogue of ZINC151209032 that has twofold 
selectivity for MT2 over MT1. c, Docked pose of ZINC151192780, an analogue for 
which the MT2 selectivity increases to 89-fold over MT1. d, Docked pose of 
ZINC485552623, which adds a bulkier 2-chloro-3-methylthiophene into a 
proposed MT2-selective hydrophobic cleft, resulting in a fully MT2-selective 
agonist without detectable MT1 activity. All docked poses are overlaid onto the 
crystallographic pose of 2-phenylmelatonin in transparent blue. e, 
Concentration–response curves of the four analogues binding to MT1 and MT2. 
Data are normalized to the melatonin response and are mean ± s.e.m. of four 
biologically independent experiments (n = 4) run in triplicate. f, Bias plots of 
ZINC482850041 and ZINC608506688 relative to melatonin signalling. Mean 
values (Supplementary Table 3) are presented as solid lines and the shading 
indicates the 95% confidence interval. Data in f are normalized to the melatonin 
response and represent mean ± s.e.m. of three biologically independent 
experiments (n = 3) run in triplicate, except for ZINC608506688 for Gi 
activation (n = 4).
Extended Data Fig. 4 | MT1-selective inverse agonists decelerate the re-
entrainment rate in vivo via MT1 receptors. Data are an extension of Fig. 3a–c. 
a–e, Representative actograms of running wheel activity in wild-type (WT) 
C3H/HeN mice treated with vehicle (VEH) (a), 30 μg melatonin (MLT) per mouse 
(b), UCSF7447 (‘7447) (c), UCSF3384 (‘3384) (d) or 300 μg luzindole (LUZ) per 
mouse (e) immediately before the new dark onset (black dots) after an abrupt 
advance in the dark onset of 6 h in a 12:12 light:dark cycle (grey, dark phase; 
white, light phase). Compounds were administered once a day for 3 days 
(see Methods for additional details). f–k, Representative actograms of running 
wheel activity for C3H/HeN mice treated with vehicle (wild-type (f), MT1KO (h), 
MT2KO ( j)) or inverse agonist UCSF7447 (wild-type (g), MT1KO (i), MT2KO (k)) 
after a 6-h advance in dark onset. Mice were kept on a 12:12 light:dark cycle. 
UCSF7447 (30 μg per mouse) was administered for three consecutive days 
immediately before the new dark onset (black dots). l, The inverse agonist 
UCSF3384 decelerates the rate of re-entrainment of the rhythm of running 
wheel activity onset in C3H/HeN wild-type mice. Data are expressed in hours 
advanced each day for wild-type mice treated with vehicle or UCSF3384 (two-
way repeated-measures ANOVA; treatment × time interaction: F16,647 = 1.99, 
P = 0.0122). m, The inverse agonist UCSF7447 does not modulate the rate of  
re-entrainment of the onset of a running wheel activity rhythm in C3H/HeN 
MT1KO mice. Data are expressed in hours advanced each day for MT1KO mice 
treated with vehicle or UCSF7447 (mixed-effect two-way repeated-measures 
ANOVA; treatment × time interaction: F16,474 = 1.44, P = 0.117). n, The inverse 
agonist UCSF7447 decelerates the rate of re-entrainment of the onset of a 
running wheel activity rhythm in C3H/HeN MT2KO mice. Data are expressed in 
hours advanced each day for MT2KO mice treated with vehicle or UCSF7447 
(mixed-effect two-way repeated-measures ANOVA; treatment × time 
interaction: F16,683 = 2.57, P = 0.000686). Data are mean + s.e.m. *P < 0.05, 
**P < 0.01; multiple comparisons were corrected using Tukey’s post-test 
(P < 0.05). The dotted line in l–n indicates the new dark onset. Additional details 
of all statistical analyses as well as n numbers for each condition can be found in 
the Methods, ‘Statistics and reproducibility’. All treatments were given as a 
subcutaneous injection.
Extended Data Fig. 5 | MT1-selective inverse agonists induce a phase advance 
in circadian activity at CT 10 that is mediated by MT1 in vivo. Data are an 
extension of Fig. 3d–f. a–e, Representative actograms of running wheel activity 
from individual C3H/HeN wild-type mice kept in constant dark (grey bars) 
treated with vehicle (a), melatonin (b), UCSF7447 (c), UCSF3384 (d) or 
luzindole (e). All treatments were 30 μg per mouse except for luzindole, which 
was 300 μg per mouse as described in the Methods. Mice were treated at dusk 
(CT 10; 2 h before the onset of running wheel activity) for three consecutive 
days (black dots). Red lines indicate the best-fit line of pre-treatment onsets 
and blue lines indicate the best-fit line of post-treatment onsets, which were 
both used for phase shift determinations (see Methods for more details). The 
corresponding quantification can be found in Fig. 3d. f–h, Representative 
actograms of running wheel activity from individual C3H/HeN wild-type mice 
kept in the constant dark treated with vehicle (f), melatonin (g) or UCSF7447  
(h; all treatments were 0.9 μg per mouse) at CT 10. The corresponding 
quantification can be found in Fig. 3d. i–k, Representative actograms of 
running wheel activity from individual C3H/HeN wild-type mice kept in the 
constant dark treated with melatonin (i) at CT 2 (10 h before the onset of 
running wheel activity) or vehicle ( j) compared with UCSF7447 (k; all 
treatments were 30 μg per mouse) at CT 6 (6 h before the onset of running 
wheel activity). The corresponding quantification can be found in Extended 
Data Fig. 7. l–q, Representative actograms of running wheel activity from 
individual C3H/HeN wild-type (l, m), MT1KO (n, o) and MT2KO (p, q) mice kept in 
constant dark treated with vehicle (white; l, n, p) or UCSF7447(blue; m, o, q; 
30 μg per mouse) at CT 10. The corresponding quantification can be found in 
Fig. 3e. r–w, Representative actograms of running wheel activity from 
individual C3H/HeN wild-type (r, s), MT1KO (t, u) and MT2KO (v, w) mice kept in 
constant dark treated with vehicle (white; r, t, v) or UCSF7447(blue; s, u, w; 
30 μg per mouse) at CT 2. The corresponding quantification can be found in 
Fig. 3f. All treatments were given by subcutaneous injection.
Extended Data Fig. 6 | Concentration–response curves and Schild plots of 
the inverse agonists UCSF7447 and UCSF3384 in cAMP assays. a, b, d, e, 
Modulation of hMT1-mediated (a, d) or hMT2-mediated (b, e) inhibition of 
isoproterenol-stimulated cAMP in HEK293T cells by melatonin in the presence 
of UCSF7447 (a, b) or UCSF3384 (d, e) for a range of concentrations. Data are 
normalized to the effect of isoproterenol alone and are mean ± s.e.m. of three 
biologically independent experiments (n = 3) run in triplicate. c, f, Schild plots 
depicting the competitive antagonism of melatonin by UCSF7447 (c) and 
UCSF3384 (f). Schild analysis of hMT1 (purple) and hMT2 (teal) show the 
competitive antagonism of UCSF7447 (hMT1, pKB = 7.4 ± 0.1, slope = 0.98 ± 0.03; 
hMT2, pKB = 6.2 ± 0.1, slope = 1.3 ± 0.4) (c) and UCSF3384 (hMT1, pA2 = 7.9 ± 0.1, 
slope = 0.80 ± 0.04; hMT2 pKB = 6.7 ± 0.1, slope = 1.0 ± 0.1) (f). Data are 
mean ± s.e.m. of three biologically independent experiments (n = 3) run in 
triplicate.
Extended Data Fig. 7 | Differential phase shift profile for the inverse agonist 
UCSF7447 compared to the agonist melatonin and a prototype antagonist 
(luzindole) across the circadian cycle. a–c, C3H/HeN mice were kept in 
constant dark and treated with vehicle, melatonin, luzindole or UCSF7447 (all 
treatments were 30 μg per mouse except for luzindole, which was 300 μg per 
mouse, subcutaneously). Mice were treated at CT 2, 6 or 10 (10, 6 or 2 h before 
the onset of running wheel activity) for three consecutive days (Methods). a, 
CT 2 phase shift data were compared using one-way ANOVA (F3,11 = 28.16, 
P = 1.85 × 10−5). b, CT 6 phase shift data were compared using one-way ANOVA 
(F3,26 = 0.61, P = 0.61). c, CT 10 phase shift data were compared using one-way 
ANOVA (F3,17 = 35.13, P = 1.66 × 10
−7). All multiple comparisons were made 
compared with vehicle using a Dunnet’s post hoc test (P < 0.05). Values for 
melatonin and UCSF7447 at CT 10 were pooled from previous data for 
comparison to luzindole. Data are mean ± s.e.m. ****P < 0.0001 for comparisons 
with vehicle. All treatments were given by subcutaneous injection.
Extended Data Table 1 | Active molecules from the initial docking screen
aCluster rank and global rank are shown; the global rank is shown in brackets (Methods) 
b,cThe log-transformed half-maximal concentration (pEC50) of the inhibition of isoproterenol-stimulated cAMP production on hMT1 or hMT2 melatonin receptors transiently expressed in HEK293T 
cells. Values in parentheses represent the percentage of the maximal inhibition normalized to the percentage of the melatonin response, except for inverse agonists, which are indicated by 
(Inverse), for which the data are normalized to percentage of basal response induced by isoproterenol. Data represent mean ± s.e.m. of the indicated number (n) of biologically independent 
experiments run in triplicate. 
dECFP4 Tanimoto coefficient (Tc) to the most similar known MT1 or MT2 ligand in ChEMBL23. 
eThe MT1/MT2 ligand in ChEMBL23 that is most similar to the docking active molecule.
Extended Data Table 2 | Some of the potent analogues from initial hits
aCompounds were selected directly from the primary docking screen and were found to be active after in vitro testing. 
bAnalogue of the initial hit. 
c,dThe pEC50 of the inhibition of isoproterenol-stimulated cAMP production on hMT1 or hMT2 melatonin receptors transiently expressed in HEK293T cells. Values in parentheses represent the 
percentage of the maximal inhibition normalized to the percentage of the melatonin response, except for inverse agonists, indicated by (Inverse), for which the data are normalized to the 
percentage of the basal response induced by isoproterenol. Data are mean ± s.e.m. of the indicated number (n) of biologically independent experiments run in triplicate.
Extended Data Table 3 | Pharmacokinetics of three melatonin receptor type-selective ligands
aCmax, maximum concentration reached in blood plasma of mice. 
bAUC, area under the plasma concentration–time curve. 
cT1/2, half-life of the compound. 
dCL, clearance from blood plasma of mice. 
eVss, volume of the distribution at steady-state.
Extended Data Table 4 | Probe pairs of in vivo tested molecules
a,bThe pEC50 of the inhibition of isoproterenol-stimulated cAMP production on hMT1 or hMT2 melatonin receptors transiently expressed in HEK293T cells. Values in parentheses represent the per-
centage of the maximal inhibition normalized to the percentage of the melatonin response for UCSF4226 and to the percentage of the basal activity for UCSF7447. Compounds were tested at 
concentrations up to 30 μM. Data are mean ± s.e.m. of the indicated number (n) of biologically independent experiments run in triplicate.
